Aspire Biopharma Holdings, Inc. (ASBP)

Nasdaq: ASBP · Pharmaceutical Preparations · Estero, FL · filing with the SEC since 2021

Full chart Alerts Compare

Grade3.5

◀ Past 3.2● Present 2.1▶ Future 4.9

5 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Aspire Biopharma Holdings, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.5/10

◀ Past3.225% of the headline

● Present2.135% of the headline

▶ Future4.940% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 4 read as filed from the record and 5 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.2/1025% of the headline grade · 1 of 3 filed, 2 estimated

Surviving crises

as filed

1.1/10

Has it survived what it has been through?

8 warning events since 2021; the latest 2026-09-29.

weight 22% of this tense · 11th percentile among 497 sector filers · read for itself

From the record

Aspire Biopharma Holdings, Inc.'s filings since 2021 show 8 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2025-10-17); an auditor change (8-K item 4.01, 3 times, the latest 2026-09-29); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2025-03-31) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

SI estimate

5.1/10

What has it actually done, year after year?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 324 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one.
What the record cannot read: Fewer than three filed years of revenue on file.
How it was reasoned: family median, 324 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Aspire Biopharma Holdings, Inc.'s track record is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Shareholder treatment

SI estimate

2.0/10

How has it treated the people who own it?

SI estimate 2.0/10, confidence 35 of 100 (one part).

weight 33% of this tense · 20th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 20% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Aspire Biopharma Holdings, Inc.'s shareholder treatment is put at 2.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 20% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.1/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

0.9/10

Is it financially healthy right now?

Leverage 586%: owes 586¢ per asset dollar.

weight 45% of this tense · 9th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Aspire Biopharma Holdings, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned less than nothing, about minus 0 cents per dollar of everything the company owns. Leverage: it owed about 586 cents per dollar of assets, and net share issuance: its share count grew 116.7% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 1% of its family
gross profit against assetsbottom 3% of its family
the share count against the year beforebottom 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

0.1/10

How strong is its position in its industry?

bottom 1% of 315 in its family; net margin -394725.1%.

weight 22% of this tense · 1st percentile among 315 sector filers · read for its customers

From the record

Aspire Biopharma Holdings, Inc.'s standing among 315 graded names in its industry family: revenue of $6 thousand in fiscal 2025 ranks in the bottom 1% by size; a net margin of -394725.1% ranks in the bottom 1% (its annual reports).

What it rests on

revenue against the family$6202.00bottom 1% of its family
net margin-394725.1%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: No officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: No officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Aspire Biopharma Holdings, Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.9/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

as filed

4.5/10

How much room does it have to grow?

bottom 45% of 273 in its family for room to expand.

weight 33% of this tense · 45th percentile among 273 sector filers · read for itself

From the record

Aspire Biopharma Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $1 million against no long-term debt tagged leaves 76.5% of its assets as net cash, top 20% of its family; cash from operations less capital spending is -79385.5% of revenue (bottom 3%); a gross margin of -1.9% (bottom 4%); research spending of 14897% of revenue (top 5%) (its annual report).

What it rests on

cash less debt against assets76.5%top 20% of its family
cash from operations less capital spending against revenue-79385.5%bottom 3% of its family
gross margin-1.9%bottom 4% of its family
research spending against revenue14897.0%top 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

SI estimate

5.0/10

What could actually drive growth from here?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 307 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one.
What the record cannot read: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned: family median, 307 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Aspire Biopharma Holdings, Inc.'s growth drivers is put at 5.0 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Aspire Biopharma Holdings, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ASBP · research, not advice